Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19925941 | 0.86 | POLB (0.50) | POLBLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17963115 | 0.85 | POLB (0.51) | POLBLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1197498 | 0.84 | LMNA (0.68) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL17137816 | 0.84 | POLB (0.64) | POLBLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17982224 | 0.84 | POLB (0.50) | POLBLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22632858 | 0.83 | POLB (0.78) | POLBLMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL6990416 | 0.83 | CYP1A2 (0.48) | POLBLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22632964 | 0.83 | CYP1A2 (0.48) | POLBLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10150643 | 0.82 | LMNA (0.47) | POLBLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12821489 | 0.81 | LMNA (0.49) | POLBLMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250122183-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025074249-A1 | NITROGEN-LINKED BENZISOXAZOLE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214214-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116171280-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022058920-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | WO | disclosed |
| WO-2020227368-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| US-20100286139-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010074947-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100152181-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009062308-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286139-A1 | AMINO PYRAZOLE COMPOUND | MCL1, MYC, PML | POLB 4096/4885LMNA 4470/4885CYP1A2 2619/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | POLB 1523/4885LMNA 1962/4885CYP1A2 254/4885 |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | POLB 2188/4885LMNA 3260/4885CYP1A2 2492/4885 |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | POLB 4264/4885LMNA 4606/4885CYP1A2 745/4885 |
| US-20250122183-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | POLB 3308/4885LMNA 2217/4885CYP1A2 723/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | POLB 1523/4885LMNA 1962/4885CYP1A2 254/4885 |
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | POLB 3358/4885LMNA 2150/4885CYP1A2 732/4885 |
| US-20100152181-A1 | AMINO PYRAZOLE COMPOUND | MCL1, MYC, PML | POLB 4096/4885LMNA 4470/4885CYP1A2 2619/4885 |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | HSP90AB1, HSP90B1, HSP90AA1 | POLB 4264/4885LMNA 4606/4885CYP1A2 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.